Researchers in the United Kingdom have uncovered genetic evidence linking the breakdown of spinal discs to altered gene activity and mineral build-up, pointing to potential drug treatments that could eventually offer an alternative to surgery for millions suffering from chronic back pain.
Back pain touches most people at some point in life, driven largely by intervertebral disc degeneration, or IVDD. This gradual breakdown of the spinal discs that cushion the bones of the spine has long lacked any pharmacological remedy. For generations, medical intervention for advanced disc disease has boiled down to a single major option: surgery. Now, a study published in Communications Biology sheds light on the biological mechanisms behind the spine’s structural decline, offering fresh avenues for therapeutic development.
Zebrafish Research Reveals How Genetic Faults Harden the Spine
To understand why genetic faults trigger disc disease, scientists from the Universities of Edinburgh and Bristol examined zebrafish bred without a working copy of a key gene. This specific gene is connected to collagen IX, a protein responsible for holding the structural fibers of spinal discs together—a genetic factor repeatedly associated with early-onset disc problems.
As the experimental fish aged, their spines mirrored human pathology with striking accuracy. The bones of the spine fused, and the tissue between vertebrae hardened due to abnormal mineral deposits. Researchers observed that this hardening was preceded by a breakdown of a supportive scaffold layer within the developing spine long before any mineral accumulation began.
Gene expression analysis revealed significant disruptions in how the body handled fat, alongside alterations in phosphate handling, vitamin A signaling, and the mTOR growth-control pathway. These biological processes are linked to mineral buildup, acting as the underlying drivers of spinal stiffening.
Targeted Interventions and Potential Drug Approches
Having identified these metabolic pathways, the research team tested several methods to curb the damage. A bone-protecting drug already used for osteoporosis, known as a bisphosphonate, successfully blocked mineral accumulation in the study subjects. Additionally, restricting food intake or administering medications designed to dampen fat metabolism effectively reduced the frequency of spinal fusions.
These experiments highlight fat metabolism and phosphate handling as promising targets for future therapeutics. The findings suggest that existing pharmaceutical agents, such as bisphosphonates already proven safe in patients, could be repurposed to slow down the structural hardening of the spine.
“For decades, surgery has been the only real answer for disc disease. By understanding the biology that drives the spine to harden, our zebrafish studies point to several ways of slowing it down, including a drug already used safely in patients. There’s more work to do, but for a condition that’s affected people for generations without a treatment in sight, this is super exciting.”
Dr Erika Kague, study lead from the University of Edinburgh’s Institute of Genetics and Cancer
Broader Implications for Millions Living With Back Pain
The discovery carries significant public health implications.
“This research shows how publicly funded discovery bioscience can generate the knowledge needed to address major health challenges. By revealing new knowledge of how healthy biological processes break down in ageing-related spinal disc degeneration, the study opens up promising avenues for future treatment development.”
Dr Jef Grainger, Executive Director – Bioscience Advancing Knowledge at BBSRC
While the study provides a critical conceptual shift away from purely surgical management, researchers caution that clinical applications will require extensive follow-up. Arthritis UK, which co-funded the project alongside the Biotechnology and Biological Sciences Research Council, noted that while the work brings fresh hope, translating these animal-model discoveries into approved human therapies remains a challenge for future clinical development.
Worth a look
